Pegylated interferon-alpha for treating chronic hepatitis E virus infection after liver transplantation.
This study assessed the effect of a 3-month course of pegylated interferon-alpha-2a (Peg-IFN-alpha-2a) in 3 liver transplant patients with chronic active hepatitis E. A virological response was sustained for 6 and 5 months in 2 patients after Peg-IFN-alpha-2a therapy was completed. A relapse was observed in the third patient.
Kamar
Nassim
N
Department of Nephrology, Dialysis and Organ Transplantation, Centre Hospitalier Universitaire, Toulouse, France. kamar.n@chu-toulouse.fr
Rostaing
Lionel
L
Abravanel
Florence
F
Garrouste
Cyril
C
Esposito
Laure
L
Cardeau-Desangles
Isabelle
I
Mansuy
Jean Michel
JM
Selves
Janick
J
Peron
Jean Marie
JM
Otal
Philippe
P
Muscari
Fabrice
F
Izopet
Jacques
J
D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D016751:Hepatitis E / Q000188:drug therapy*; D006521:Hepatitis, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D011994:Recombinant Proteins; D055502:Secondary Prevention
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C100416:peginterferon alfa-2a